Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

BACKGROUND: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. OBJECTIVE: To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss p...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mult Scler
Glavni autori: Cuker, Adam, Bass, Ann D, Nadj, Congor, Agius, Mark A, Steingo, Brian, Selmaj, Krzysztof W, Thoits, Timothy, Guerreiro, Alexandre, Van Wijmeersch, Bart, Ziemssen, Tjalf, Meuth, Sven G, LaGanke, Christopher C, Thangavelu, Karthinathan, Rodriguez, Claudio E, Baker, Darren P, Margolin, David H, Jannsens, Ann
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2019
Teme:
Original Research Papers
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6950888/
https://ncbi.nlm.nih.gov/pubmed/30785358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458518816612
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items